Articles related to TYPE 2 DIABETES

A 2025 AACE consensus statement introduced a complication-centric, staged framework for managing adults with obesity and adiposity-based chronic disease, with drug selection tied to specific obesity-related complications rather than weight loss alone.

The FDA approved inhaled insulin (Afrezza) for pediatric patients aged 6 and older with type 1 or type 2 diabetes, based on phase 3 trial data and long-term safety evidence from manufacturer-sponsored studies.

A retrospective cohort study of 349,168 propensity-matched patients with diabetes found a hazard ratio of 2.22 for nonarteritic anterior ischemic optic neuropathy among semaglutide users compared with non-GLP-1 RA antidiabetic therapy users, with elevated risk emerging at two years and persisting through four years of follow-up.

A systematic review of 27 studies found behavioral sleep interventions — particularly CBT-I and sleep hygiene — reduced BMI and body weight in adults with poor sleep health, with the largest effects among patients with obesity.

A phase 3 head-to-head RCT of 689 patients found intravitreal brolucizumab preserved visual acuity at 54 weeks while panretinal photocoagulation patients lost a mean of approximately 4 letters, though intraocular inflammation rates were higher with brolucizumab.

“Selecting a GLP-1 receptor agonist over another antihyperglycemic drug could plausibly confer ancillary benefit” in patients at high risk for or living with an SUD. — Study authors